Get the Stockscreener App
7.3119
0.52%
-0.0381
Galecto Inc stock is traded at $7.3119, with a volume of 14,311.
It is down -0.52% in the last 24 hours and up +96.56% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$7.35
Open:
$7.2
24h Volume:
14,311
Relative Volume:
0.01
Market Cap:
$9.68M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-5.0427
EPS:
-1.45
Net Cash Flow:
$-36.91M
1W Performance:
-13.26%
1M Performance:
+96.56%
6M Performance:
+161.14%
1Y Performance:
+6.74%
1-Day Range:
$7.18
$7.4941
1-Week Range:
$7.02
$8.355
52-Week Range:
$2.01
$31.70
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Compare GLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
7.31 | 9.74M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.76 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
655.00 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.91 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
813.02 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
190.00 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
Galecto Inc Stock (GLTO) Latest News
Can Galecto Inc. stock weather global recessionJuly 2025 Update & AI Forecast Swing Trade Picks - newser.com
Combining price and volume data for Galecto Inc.Portfolio Risk Report & Fast Exit Strategy with Risk Control - newser.com
How to monitor Galecto Inc. with trend dashboardsQuarterly Earnings Summary & Safe Entry Zone Identification - newser.com
Will Galecto Inc. stock maintain dividend yieldTrade Entry Report & Weekly Chart Analysis and Guides - newser.com
Is a relief rally coming for Galecto Inc. holdersJuly 2025 Reactions & Free Daily Entry Point Trade Alerts - newser.com
Can Galecto Inc. stock hit analyst price targetsTrade Risk Report & Free Real-Time Volume Trigger Notifications - newser.com
Is Galecto Inc. stock cheap at current valuationQuarterly Growth Report & High Accuracy Investment Entry Signals - newser.com
Why Galecto Inc. stock remains undervalued2025 Growth vs Value & AI Powered Market Entry Strategies - newser.com
Is Galecto Inc. stock attractive for income investorsJuly 2025 Update & Growth Oriented Trading Recommendations - Fundação Cultural do Pará
Using portfolio simulators with Galecto Inc. includedQuarterly Performance Summary & Fast Moving Market Watchlists - newser.com
What drives Galecto Inc stock priceRisk-Reward Ratio Analysis & Access Free Tools and Start Investing - earlytimes.in
Is Galecto Inc. stock attractive for growth ETFsTrade Volume Summary & Verified Swing Trading Watchlist - newser.com
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galecto Inc Stock (GLTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Winslow Garrett | General Counsel |
Jul 03 '25 |
Sale |
3.39 |
260 |
881 |
1,429 |
| Firmani Lori | Interim CFO |
Jul 03 '25 |
Sale |
3.39 |
147 |
498 |
692 |
| Winslow Garrett | General Counsel |
Jan 03 '25 |
Sale |
5.60 |
471 |
2,638 |
1,009 |
| Firmani Lori | Interim CFO |
Jan 03 '25 |
Sale |
5.63 |
261 |
1,469 |
465 |
| Schambye Hans T. | Chief Executive Officer |
Jan 03 '25 |
Sale |
5.60 |
1,341 |
7,510 |
3,397 |
1.19%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):